MARKET

ALBO

ALBO

Albireo Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

35.08
-1.60
-4.36%
After Hours: 34.50 -0.58 -1.65% 16:54 02/25 EST
OPEN
36.12
PREV CLOSE
36.68
HIGH
37.44
LOW
34.87
VOLUME
225.70K
TURNOVER
--
52 WEEK HIGH
49.00
52 WEEK LOW
11.26
MARKET CAP
669.23M
P/E (TTM)
-5.7011
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Albireo Pharma (ALBO) Received its Third Buy in a Row
After William Blair and Wedbush gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from Needham.
SmarterAnalyst · 7h ago
8-K: ALBIREO PHARMA, INC.
(EDGAR Online via COMTEX) -- 0001322505 false 0001322505 2021-02-25 2021-02-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 9h ago
10-K: ALBIREO PHARMA, INC.
Edgar Online - (EDG = 10Q, 10K) · 11h ago
Albireo Pharma Q4 EPS $(1.30) Beats $(1.94) Estimate, Sales $2.72M Beat $2.34M Estimate
Albireo Pharma (NASDAQ:ALBO) reported quarterly losses of $(1.30) per share which beat the analyst consensus estimate of $(1.94) by 32.99 percent. This is a 128.07 percent decrease over losses of $(0.57) per share from
Benzinga · 11h ago
Albireo Pharma: ASSERT Global Pivotal Phase 3 Trial in Alagille Syndrome Initiated and Enrolling >ALBO
Albireo Pharma: ASSERT Global Pivotal Phase 3 Trial in Alagille Syndrome Initiated and Enrolling >ALBO
Dow Jones · 12h ago
Albireo Pharma: BOLD Global Pivotal Phase 3 Study in Biliary Atresia Initiated and Enrolling >ALBO
Albireo Pharma: BOLD Global Pivotal Phase 3 Study in Biliary Atresia Initiated and Enrolling >ALBO
Dow Jones · 12h ago
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 12h ago
Albireo Pharma EPS beats by $0.59, beats on revenue
Albireo Pharma (ALBO): Q4 GAAP EPS of -$1.30 beats by $0.59.Revenue of $2.72M (-57.7% Y/Y) beats by $0.38M.Press Release
Seekingalpha · 12h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALBO. Analyze the recent business situations of Albireo Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALBO stock price target is 70.71 with a high estimate of 79.00 and a low estimate of 65.00.
EPS
Institutional Holdings
Institutions: 169
Institutional Holdings: 19.67M
% Owned: 103.13%
Shares Outstanding: 19.08M
TypeInstitutionsShares
Increased
44
2.79M
New
43
-1.15M
Decreased
29
1.22M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.53%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Independent Director
David Chiswell
President/Chief Executive Officer/Director
Ronald Cooper
Chief Financial Officer/Treasurer
Simon Harford
Chief Human Resource Officer
Michelle Graham
Chief Scientific Officer
Jan Mattsson
General Counsel/Secretary
Jason Duncan
Other
Martha Carter
Other
Patrick Horn
Other
Pamela Stephenson
Independent Director
Michael Gutch
Independent Director
Roger Jeffs
Independent Director
Anne Klibanski
Independent Director
Stephanie Okey
Independent Director
Davey Scoon
  • Dividends
  • Splits
  • Insider Activity
No Data
About ALBO
Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).

Webull offers kinds of Albireo Pharma Inc stock information, including NASDAQ:ALBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALBO stock methods without spending real money on the virtual paper trading platform.